Jean-Christophe Harmange

An inhibitor of KDM5 demethylases reduces survival of drug-tolerant cancer cells

Maia Vinogradova, Victor Gehling, Amy Gustafson et al. · Nature Chemical Biology · 2016 · 357 citations · Full text

Medicine, Oncology, Pharmacology +14

Identification of (<i>R</i>)-<i>N</i>-((4-Methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1<i>H</i>-indole-3-carboxamide (CPI-1205), a Potent and Selective Inhibitor of Histone Methyltransferase EZH2, Suitable for Phase I Clinical Trials for B-Cell Lymphomas

Rishi G. Vaswani, Victor Gehling, Les A. Dakin et al. · Journal of Medicinal Chemistry · 2016 · 220 citations · Full text

Medicine, Oncology, Pharmacology +16

Identification of a Benzoisoxazoloazepine Inhibitor (CPI-0610) of the Bromodomain and Extra-Terminal (BET) Family as a Candidate for Human Clinical Trials

Brian K. Albrecht, Victor Gehling, Michael C. Hewitt et al. · Journal of Medicinal Chemistry · 2016 · 215 citations · Full text

Medicine, Oncology, Pharmacology +15

Design, Synthesis, and Evaluation of Orally Active Benzimidazoles and Benzoxazoles as Vascular Endothelial Growth Factor-2 Receptor Tyrosine Kinase Inhibitors

Michele Potashman, James Bready, Angela Coxon et al. · Journal of Medicinal Chemistry · 2007 · 167 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +16

Identification of EZH2 and EZH1 Small Molecule Inhibitors with Selective Impact on Diffuse Large B Cell Lymphoma Cell Growth

Shivani Garapaty-Rao, Christopher G. Nasveschuk, Alexandre Gagnon et al. · Chemistry & Biology · 2013 · 154 citations

Medicine, Oncology, Pharmacology +8